Immunohistochemical Detection of 13(R)-hydroxyoctadecadienoic Acid in Atherosclerotic Plaques of Human Carotid Arteries Using a Novel Specific Antibody by Shibata, Noriyuki et al.
Acta Histochem. Cytochem. 42 (6): 197–203, 2009
doi:10.1267/ahc.09022
© 2009 The Japan Society of Histochemistry and Cytochemistry
Advance Publication
AHC Acta Histochemica et Cytochemica 0044-5991 1347-5800 Japan Society of Histochemistry and Cytochemistry Tokyo, Japan AHC09022 10.1267/ahc.09022 Regular Article
Immunohistochemical Detection of 13(R)-hydroxyoctadecadienoic Acid in 
Atherosclerotic Plaques of Human Carotid Arteries Using a Novel Specific Antibody
Noriyuki Shibata1, Sono Toi2, Takahiro Shibata3, Koji Uchida3, Hiroyuki Itabe4, 
Tatsuo Sawada1, Takakazu Kawamata5, Yoshikazu Okada6, Shinichiro Uchiyama2 
and Makio Kobayashi1
1Department of Pathology, Tokyo Women’s Medical University, Tokyo, Japan, 2Department of Neurology, Tokyo Women’s Medical 
University, Tokyo, Japan, 3Laboratory of Food and Biodynamics, Nagoya University Graduate School of Bioagricultural Sciences, 
Nagoya, Japan, 4Department of Biological Chemistry, Showa University School of Pharmaceutical Sciences, 5Department of 
Neurosurgery, Yachiyo Medical Center, Yachiyo, Japan and 6Department of Neurosurgery, Tokyo Women’s Medical University, 
Tokyo, Japan
Correspondence to: Noriyuki Shibata, M.D., Ph.D., Associate
Professor of Pathology, Tokyo Women’s Medical University, 8–1
Kawada-cho, Shinjuku-ku, Tokyo 162–8666, Japan. E-mail:
shibatan@research.twmu.ac.jp
?? Received August 21, 2009; accepted October 25, 2009; published online December 22, 2009
© 2009 The Japan Society of Histochemistry and Cy- 13-Hydroxyoctadecadienoic acid (13-HODE) is a major component of oxidized low density
lipoprotein (OxLDL), which has been shown to have a crucial role in atherogenesis. Of the
13-HODE stereoisomers, 13(S)-HODE and 13(R)-HODE, little is known about the latter in
contrast to the former. To detect 13(R)-HODE in atherosclerotic lesions, we prepared a
mouse monoclonal antibody against 13(R)-HODE. Competitive enzyme-linked immuno-
sorbent assay clarified the selective reaction of a clone mAb 13H1 with both free and bovine
serum albumin-conjugated forms of 13(R)-HODE but not other oxidized lipids including
13(S)-HODE. Immunohistochemical analysis revealed the colocalization of 13(R)-HODE
immunoreactivity with the OxLDL marker oxidized phophatidylcholine immunoreactivity in
vascular endothelial cells, macrophages and migrating vascular smooth muscle cells in
atherosclerotic plaques of human carotid arteries. The present results provide in vivo
evidence for the formation of 13(R)-HODE in atherosclerotic lesions of carotid arteries.
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I. Introduction
Emerging evidence suggests a pivotal role for oxidized
low density lipoprotein (OxLDL) in atherogenesis [2, 15,
22]. It has been shown that OxLDL contains a variety of
oxidized lipids including oxidized fatty acids, oxidized free
cholesterols and cholesteryl esters, and oxidized phospho-
lipids and hydroxyalkenals. 13-Hydroxyoctadecadienoic
acid (13-HODE) is one of the major oxidized fatty acids
[11, 23] and a major component of OxLDL detected in
atherosclerotic lesions [6, 21]. Several studies have demon-
strated that 13-HODE exerts anti-inflammatory effects as
a ligand of peroxisome proliferator-activated receptor-
gamma (PPARγ) [17], promotes macrophage OxLDL up-
take [24], and inhibits endothelial cell/platelet interaction
[4, 12], cancer cell metastasis and proliferation [18, 20]
and triacylglycerol-rich lipoprotein secretion [16].
There  are  two  stereoisomers  of  13-HODE,  13-
sinister-HODE [13(S)-HODE] and 13-rectus-HODE [13(R)-
HODE]. While 13(S)-HODE is a 15-lipoxygenase (15-
LOX) metabolite of linoleic and arachidonic acids [3, 13,
25], 13(R)-HODE is nonenzymatically formed in the
presence of oxidative stress [1, 8, 19]. Several studies
have suggested implications for 13(S)-HODE in a variety
of disorders such as atherosclerosis, thrombosis, inflam-
mation, and malignancies [3, 13, 25]. However, little is
known about the biological actions of 13(R)-HODE. It hasShibata et al. 198
been shown that atherosclerotic plaque possesses increased
15-LOX activity but contain substantial levels of 13(R)-
HODE rather than 13(S)-HODE [6]. Given that 15-LOX
has a dual roles in atherogenesis because of the anti- and
pro-inflammatory effects of its metabolites in OxLDL
[25], it is controversial that 15-LOX and 13(S)-HODE play a
critical role in the pathological processes of atherosclerosis.
Thus, it is predicted that 13(R)-HODE may be involved in
the pathomechanism of atherosclerosis. In the present
study, we developed a monoclonal antibody (mAb) against
13(R)-HODE to detect this substance in vivo. This is the
first report showing immunohistochemical localization of
13(R)-HODE in the atherosclerotic lesions of human carotid
arteries.
II. Materials and Methods
Materials
13(R)-HODE, 13(S)-HODE, 9(R)-HODE, 9(S)-HODE,
13-oxooctadecadienoic acid (13-oxo-ODE) and linoleic acid
(Fig. 1A) were purchased from Cayman Chemical Co. (Ann
Arbor, MI, USA). Keyhole limpet hemocyanin (KLH),
1-ethyl-3-(dimethylaminopropyl)carbodiimide (EDC), and
sulfo-N-hydroxysuccimide (sulfo-NHS) were obtained
from Pierce (Rockford, IL, USA). Horse radish peroxidase
(HRP)-conjugated goat anti-mouse IgG was purchased from
MPBiomedicals, LLC (Solon, OH, USA).
Development of a monoclonal antibody directed to 
13(R)-HODE
To evaluate the contribution of 13(R)-HODE to mech-
anisms of pathological conditions including atherosclerosis,
we attempted to develop an mAb specific for this substance.
The hapten used in the present study was 13(R)-HODE that
was covalently attached to the carrier protein KLH using
EDC and sulfo-NHS as described previously [7]. Female
BALB/c mice were immunized three times with the 13(R)-
HODE-KLH conjugates. We observed an enhanced immune
response to the 13(R)-HODE-conjugated bovine serum
albumin (BSA) in the immunized BALB/c mice (data not
shown). Splenocytes derived from the immunized mice were
fused with P3U1 murine myeloma cells and cultured in
hypoxanthine/aminopterin/thymidine selection medium.
Culture media of the hybridoma were screened using
enzyme-linked immunosorbent assay (ELISA), employing
pairs of wells of microtiter plates coated with 13(R)-HODE-
BSA conjugates (0.5 μg of protein/well). After incubation
with 100 μL of hybridoma supernatants, and with interven-
ing washes with phosphate-buffered saline (PBS), pH 7.6,
containing 0.05% Tween 20 (PBS-T), the wells were incu-
bated with HRP-conjugated goat anti-mouse IgG followed
by a substrate solution containing 0.5 mg/mL 1,2-phenyl-
enediamine. The affinity of supernatants from obtained
clones with oxidized lipids was determined by competitive
ELISA. A competitor was incubated with the antibody for
20 hr at 4°C to yield competitor/antibody mixtures at vari-
able concentrations of the competitor. A 100 μL aliquot of
the mixtures was added to each well and incubated for 1 hr
at 37°C. After discarding the supernatants and washing three
times with Tris-buffered saline (TBS), pH 7.5, containing
0.05% Tween 20 (TBS-T), wells were filled with the sec-
ondary antibody followed by peroxidase substrate. Results
were expressed as the ratio, B/B0 (B=absorbance in the
presence of competitor; B0=absorbance in the absence of
competitor).
Immunohistochemical analysis of 13(R)-HODE in carotid 
arteries
The primary antibodies used for immunohistochemis-
try were 13H1 as well as mouse anti-CD34 IgG1 (Clone No.
QBEnd/10; diluted 1:100; Novocastra Laboratories, New-
castle upon Tyne, UK), mouse anti-CD68 IgG1 (Clone No.
Fig. 1. Comparision of reactivity of mAb 13H1 with oxidized lipids.
(A) Molecular structures of oxidized lipids examined. (B) Results
of competitive ELISA on microtiter plate wells coated with 13(R)-
HODE-BSA. Abbreviations: BSA, bovine serum albumin; ELISA,
enzyme-linked immunosorbent assay; HODE, hydroxyoctadecadi-
enoic acid; oxo-ODE, oxooctadecadienoic acid.13(R)-HODE in Carotid Atherosclerosis 199
KP-1; diluted 1:10,000; Dako Cytomation, Kyoto, Japan),
mouse anti-α-smooth muscle actin (SMA) IgG1 (Clone No.
1A4; diluted 1:1,000; Dako), mouse anti-oxidized phos-
phatidylcholine (OxPC) IgM (Clone No. DLH3; diluted
1:3,000) [9], rabbit anti-PPARγ IgG (Cat. No. sc-7196;
diluted 1:500; Santa Cruz Biotechnology, Santa Cruz,
CA, USA), and rabbit anti-CD36 IgG (Cat. No. sc-9154;
diluted 1:300; Santa Cruz). CD34, CD68, SMA and OxPC
were used as markers of vascular endothelial cells (VECs),
macrophages, vascular smooth muscle cells (VSMCs) and
OxLDL, respectively.
This investigation was approved by the local ethics
comission in accordance with the Declaration of Helsinki,
revised 2008 and carried out on six carotid atherosclerosis
patients who underwent carotid endoarterectomy (CEA).
Multiple 10-μm-thick sections of freshly frozen CEA speci-
mens embedded in optimal cutting temperature (OCT) com-
pound (Sakura Fine Chemical, Tokyo, Japan) were used for
hematoxylin-eosin (H&E) staining and immunohistochemi-
cal staining. Sections were air-dried, postfixed for 10 min at
4°C in 100% acetone, rehydrated, quenched for 10 min at
4°C with 3% hydrogen peroxide, rinsed in PBS, pretreated
for 20 min at room temperature with 3% skim milk in PBS,
and subsequently incubated overnight at 4°C with the prima-
ry antibodies. Sections processed with omission of the pri-
mary antibodies or incubated with nonimmune serum de-
rived from the same animal species as those producing the
antibodies served as negative reaction controls. Antibody
binding was visualized by the polymer-immunocomplex
(PIC) method using the appropriate Envision system (Dako),
according to the manufacturer’s instructions. 3,3'-Diamino-
benzidine tetrahydrochloride (DAB) was the chromogen,
and hematoxylin, the counterstain. To verify the specificity
of 13H1, preabsorption test was performed as the following;
some sections were incubated with the antibody preabsorbed
with 1.0 mg/mL 13(R)-HODE-BSA conjugates in PBS.
Immunohistochemical localization of 13(R)-HODE was
verified by comparison with consecutive sections stained
with H&E or immunostained for targeted antigens such as
CD34, CD68, SMA, OxPC, PPARγ and CD36.
III. Results
Characterization of anti-13(R)-HODE antibody
Hybridomas that produced and released antibodies
against 13(R)-HODE were detected by ELISA on plates
coated with the 13(R)-HODE-coupled BSA, and five clones
reactive with the coated antigen were obtained. Among
them, two clones named 13H1 and 13H2 showed relatively
high reactivity with coated antigen (data not shown). Final-
ly, one clone, 13H1, associated with good growth and dis-
tinctive recognition of 13(R)-HODE was selected and used
in the present study. In spite of an extensive screening of
hybridomas that produced monoclonal antibodies specific
for 13(R)-HODE, it is still unknown whether the antibody
may recognize epitopes originating from other oxidized
lipids. To answer this question, the specificity of mAb 13H1
was verified by competitive ELISA (Fig. 1B). The antibody
13H1 selectively recognized the coated antigen 13(R)-
HODE-BSA as well as the competitor antigen 13(R)-
HODE. By contrast, the antibody showed no significant
crossreactivity with 13(S)-HODE, 9(R)-HODE, 9(S)-
HODE, 13-oxo-ODE, or linoleic acid. These results suggest
that mAb 13H1 exclusively recognizes 13(R)-HODE.
Fig. 2. Immunohistochemical observations at a low magnification
of consecutive sections immunostained for 13(R)-HODE (A),
CD68 (B) and SMA (C) in an atherosclerotic plaque of a human
carotid artery. PIC method using DAB (A–C). Bar=1 mm. Abbrevi-
ations: DAB, 3,3'-diaminobenzidine tetrahydrochloride; HODE,
hydroxyoctadecadienoic acid; PIC, polymer-immunocomplex.Shibata et al. 200
Fig. 3. Negative staining on a section incubated with 13H1 preabsorbed with excess 13(R)-HODE-BSA conjugates (B) and identification of
13(R)-HODE immunoreactivity (A, C, E, G) in CD34-immunoreactive VECs (D), CD68-immunoreactive macrophages (F) and SMA-
immunoreactive migrating VSMCs (H) in human atherosclerotic carotid arteries. Areas of panels (A, C, E, G) are the same as those of panels
(B, D, F, H) on consecutive sections, respectively. Panels (A, B) show staining on a fatty streak. Solid and blank arrowheads and asterisks
indicate VECs, macrophages and migrating VSMCs, respectively. PIC method using DAB (A–H). Bar=100 μm. Abbreviations: BSA, bovine
serum albumin; DAB, 3,3'-diaminobenzidine tetrahydrochloride; HODE, hydroxyoctadecadienoic acid; PIC, polymer-immunocomplex; SMA,
α-smooth muscle actin; VECs, vascular endothelial cells; VSMCs, vascular smooth muscle cells.13(R)-HODE in Carotid Atherosclerosis 201
Fig. 4. Comparison of immunohistochemical distribution of 13(R)-HODE (A, C, E, G) with OxPC (B, D), PPARγ (F) and CD36 (H) in lesional
cells of human atherosclerotic carotid arteries. Areas of panels (A, C, E, G) are the same as those of panels (B, D, F, H) on consecutive sections,
respectively. Solid and blank arrowheads and arrows indicate VECs, macrophages and migrating VSMCs, respectively. PIC method using DAB
(A–H). Bar=100 μm. Abbreviations: DAB, 3,3'-diaminobenzidine tetrahydrochloride; HODE, hydroxyoctadecadienoic acid; OxPC, oxidized
phosphatidylcholine; PIC, polymer-immunocomplex; PPARγ, peroxisome proliferator-activated receptor-gamma; VECs, vascular endothelial
cells; VSMCs, vascular smooth muscle cells.Shibata et al. 202
Immunohistochemical localization of 13(R)-HODE in 
atherosclerotic lesions
No immunoreaction product deposit was detectable on
negative reaction control sections (data not shown) or 13(R)-
HODE-preabsorbed sections (Fig. 3A, B). At a low magnifi-
cation, areas immunoreactive for 13(R)-HODE included
those for CD68 and SMA (Fig. 2). At a higher magnifica-
tion, 13(R)-HODE immunoreactivity was localized in the
cytoplasm of CD34-immunoreactive VECs lining luminal
surface of carotid arteries (Fig. 3C, D) and neovasculatures,
CD68-immunoreactive macrophages (Fig. 3E, F), and
SMA-immunoreactive migrating VSMCs (Fig. 3G, H). The
determinants of 13(R)-HODE were colocalized and super-
imposed with those of OxPC, PPARγ and CD36 in these le-
sional cells (Fig. 4). These findings were observed in fatty
streaks as initial lesions as well as advanced lesions. The
immunoreactivities for the examined substances including
13(R)-HODE in the lesional cells were readily detectable
and pronounced in macrophage-enriched plaque (Figs. 2–4),
but by contrast were only very weak or undetectable in
macrophage-lacking plaque (data not shown). There was
no significant difference in immunostaining patterns for
13(R)-HODE between superficial and deep layers of athero-
sclerotic plaque as shown at a low magnification view.
IV. Discussion
In the present study, we produced mAb 13H1 that se-
lectively recognized 13(R)-HODE and distinguished it from
its isomer 13(S)-HODE and other oxidized lipids. Given that
there is only a little alteration in molecular structures be-
tween 13(R)-HODE and 13(S)-HODE, it is evident that the
epitope that 13H1 recognizes exists in a limited part of this
substance including the 13(R)-OH group. Moreover, com-
petitive ELISA revealed the reactivity of mAb 13H1 with
the coated antigen BSA-conjugated 13(R)-HODE as well as
the competitor antigen 13(R)-HODE. Our immunohisto-
chemical finding of the colocalization of the 13(R)-HODE
determinants with the OxPC determinants in the athero-
sclerotic lesions of carotid arteries indicates that OxLDL
contains 13(R)-HODE as both the free and protein-bound
forms in atherosclerotic lesions. The fact that 13(R)-HODE
immunoreactivity was more intense in the macrophage-
enriched plaque as compared with the macrophage-lacking
plaque shows that tissue levels of this substance depends on
those of OxLDL. Also the fact that 13(R)-HODE immuno-
reactivity was less intense in the extracellular matrix of
plaque neointima, as compared with VECs, macrophages,
and migrating VSMCs, suggests that the lesional cells
took up extracellular OxLDL containing 13(R)-HODE and
concentrated them in these cells. This is in keeping with an
in vitro study showing 13-HODE uptake induced by cul-
tured VECs under increased permeability conditions [4].
However, it is to be considered with the caveat that 13(R)-
HODE could be nonenzymatically formed in these cells
after uptake. This is attributable to evidence for increased
oxidative stress in VECs, macrophages, and VSMCs, all
of which show activation of NADPH oxidase, phospho-
lipase A2, xanthine oxidase, and nitric oxide synthases as
well as accumulation of oxidative modification products of
nucleic acids, lipids, and proteins [5].
There have been only a few reports showing the biolog-
ical actions of 13(R)-HODE. A previous study indicated that
13(R)-HODE exerts an antagonizing effect on thromboxane
A2-induced platelet aggregation, and that this effect was
stronger than that of 13(S)-HODE [12]. This may conflict
with another fact that PPARγ agonists including 13-HODE
upregulate plasminogen activator inhibitor type-1 (PAI-1) in
cultured human endothelial cells [14]. These observations
suggest that 13(R)-HODE regulates a balance between
coagulative and fibrinolytic activities. Additionally, it has
been shown that 13-HODE upregulates the class B scaven-
ger receptor CD36, which we detected in the lesional cells
of atherosclerotic plaques in this study, in macrophages
via a PPARγ-dependent mechanism [10]. Thus, as an earlier
report showing the greater levels of the nonenzymatically
formed 13(R)-HODE as compared with the enzymatically
produced 13(S)-HODE in atherosclerotic lesions [6], it is
likely that 13(R)-HODE as well as 13(S)-HODE acts as an
agonist of PPARγ, which is an anti-inflammatory transcrip-
tion factor.
Collectively, we successfully demonstrated immuno-
histochemical localization of 13(R)-HODE in VECs, mac-
rophages, and migrating VSMCs in atherosclerotic lesions
of human carotid arteries, using a novel specific monoclonal
antibody. The colocalization of 13(R)-HODE immunoreac-
tivity with immunoreactivities for OxPC, PPARγ, and
CD36 in the lesional cells could indicate that 13(R)-HODE
is a major component of OxLDL, and points to the possi-
bility that 13(R)-HODE may induce CD36 via a PPARγ-
dependent mechanism. However, since OxLDL contains
both proinflammatory and antiinflammatory lipid media-
tors [2, 15, 22], it remains to be determined whether 13-
HODE in OxLDL may exert its antiinflammatory effects
on atherosclerosis. For elucidating this issue, it is neces-
sary to obtain direct evidence that 13(R)-HODE derived
from athreosclerotic lesions activates PPARγ and con-
sequently upregulates PPARγ-dependent anti-inflammatory
gene products.
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